Assessment Status |
Rapid Review Complete |
HTA ID |
24001 |
Drug |
Liraglutide |
Brand |
Saxenda® |
Indication |
Liraglutide is indicated as an adjunct to a healthy nutrition and increased physical activity for weight management in adolescent patients from the age of 12 years and above with: • obesity (body mass index (BMI) corresponding to ≥30 kg/m2 for adults by international cut-off points) and • body weight above 60 kg* |
Rapid review commissioned |
05/01/2024 |
Rapid review completed |
09/02/2024 |
Rapid review outcome |
A full HTA is not recommended. The NCPE recommends that liraglutide not be considered for reimbursement at the submitted price*. |
*The Applicant is requesting reimbursement in a subgroup of the licensed population, namely:
Adolescent patients between the ages 12 to 16 years with a BMI greater than the 99.5th percentile and two or more of the following co-morbidities:
- Uncontrolled metabolic complications.
- Biomechanical complications requiring treatment or limited mobility.
- Shortness of breath.
- Significant psychosocial complications or concerns.
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.